GSK Reports Strong Q1 2024 with £7.4B Revenue and £2.3B Vaccine Sales

On May 6, GSK released its Q1 2024 financial report, which showed: total revenue of £7.4 billion, including COVID-19 solutions growth of 10%, excluding COVID-19 solutions growth of 13%.

By region, the three major sectors have made equal progress, achieving a strong start in 2024. The vaccine sector sold £2.3 billion, including a 16% increase with the COVID-19 solution and a 22% increase without it; the specialty medicines sector sold £2.5 billion, including a 17% increase with the COVID-19 solution and a 19% increase without it, with a 14% increase including HIV; the general medicines sector sold £2.6 billion, with a 1% increase.

Moreover, the core operating profit reached £2.4 billion, with a 27% increase including the COVID-19 solution and a 35% increase excluding it; total earnings per share were 25.7 pence, down 19%; core earnings per share were 43.1 pence, with a 28% increase including the COVID-19 solution and a 37% increase excluding it; dividend was 15 pence.

GSK also disclosed in its financial report that there are currently 72 vaccines and drugs under development, with four of them showing positive Phase III data.

Editor: Mu Mian

Disclaimer: This article is a reprint from Yaozhi.com. All images and text are copyrighted by the original author. The purpose of the reprint is to convey more information and does not represent the views of this platform. If there are any issues regarding content, copyright, or other matters, please leave a message on this platform, and we will address it promptly.